JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 6 No. 4, July 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL REVIEWS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

The Pharmacologic Treatment of Anxiety and Depression in African Americans

Considerations for the General Practitioner

Tony L. Strickland, PhD; Richard Stein, PhD; Lin Keh-Ming, MD, MPH; Emile Risby, MD; Ronald Fong, MD

Arch Fam Med. 1997;6(4):371-375.


Abstract

A growing pool of recent research points to the importance of ethnicity in psychopharmacologic management of depression and anxiety disorders, with sometimes profound implications for efficacy and safety. Such research has provided provocative findings that illustrate important interethnic pharmacogenetic, pharmacokinetic, and pharmacodynamic differences, especially for African Americans. We did a systematic literature review of psychopharmacologic treatment considerations among African Americans with anxiety and mood disturbance seen by primary care physicians, who provide most psychopharmacologic treatment. The findings commonly point to a greater percentage of "poor metabolizers" among African Americans compared with Euro-Americans. General treatment considerations include greater attention to adverse effects and better clinical response and poorer compliance for a given dose, potential need for lower starting doses and slower increases, use of plasma drug levels if available, determination of past responses to a similar drug, and integration of pharmacogenetic information into an overall socioculturally and ethnically sensitive approach to assessment and treatment.



Author Affiliations

From the Biobehavioral Research Center and Laboratory, Department of Psychiatry and Human Behavior (Drs Strickland and Stein) and the Division of Hypertension and Nephrology (Dr Fong), Charles R. Drew University of Medicine and Science, Los Angeles, Calif; the School of Medicine, University of California-Los Angeles (Dr Strickland), Research Center on the Psychobiology of Ethnicity, Harbor-UCLA Medical Center (Drs Strickland and Lin); and the Department of Psychiatry, Emory University School of Medicine, Atlanta, Ga (Dr Risby).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ethnicity and psychopharmacology
Chaudhry et al.
J Psychopharmacol 2008;22:673-680.
ABSTRACT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.